USFDA cautions Aurobindo Pharma's oral solids formulation facility of regulatory action
Posted by
www.biotecnika.org
According to USFDA's definitions, OAI means "objectionable conditions
were found and regulatory administrative sanctions by FDA are
indicated" during inspections. The company said that it believes that
this OAI classification will not have any material impact on the
existing revenues or the supplies to its US business at this juncture.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/usfda-cautions-aurobindo-pharmas-oral-solids-formulation-facility-of-regulatory-action/articleshow/73761421.cms
Subscribe to:
Post Comments (Atom)
Post a Comment